Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PHGDH | O43175 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 5/20 | 0.42 |
| ▸ | CA7 | P43166 | 3/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 8/20 | 0.36 |
| ▸ | CA2 | P00918 | 8/20 | 0.36 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 5/20 | 0.36 |
| ▸ | CA3 | P07451 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA6 | P23280 | 1/20 | 0.36 |
| ▸ | CA5A | P35218 | 1/20 | 0.36 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1645123 | 0.77 | CA1 (0.43) | CA12TSHRCA1CA2CA9 | |
| SCHEMBL16759004 | 0.77 | — | — | |
| SCHEMBL3886688 | 0.76 | PHGDH (0.46) | PHGDHCA12CA7CA14ALDH1A1 | |
| SCHEMBL7028490 | 0.76 | PHGDH (0.46) | PHGDHCA12CA7CA14ALDH1A1 | |
| SCHEMBL3128017 | 0.76 | PHGDH (0.50) | PHGDHCA12CA7CA14ALDH1A1 | |
| SCHEMBL1646187 | 0.75 | CA1 (0.48) | CA12CA7ALDH1A1MAPTTSHR | |
| SCHEMBL22973711 | 0.74 | PHGDH (0.49) | PHGDHCA12CA7CA14ALDH1A1 | |
| SCHEMBL6677562 | 0.73 | PHGDH (0.43) | PHGDHCA12CA7CA14ALDH1A1 | |
| SCHEMBL6044392 | 0.73 | PHGDH (0.40) | PHGDHCA12CA7CA14ALDH1A1 | |
| SCHEMBL3631455 | 0.71 | KDM4E (0.37) | ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011059459-A1 | PHYSICAL CHARACTERIZATION OF OLIGONUCLEOTIDES CONJUGATES | REGADO BIOSCIENCES, INC (US) | 2011-05-19 | — | — | WO | claimed |
| US-6867294-B1 | Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages | ISIS PHARMACEUTICALS, INC. (US) | 2005-03-15 | — | — | US | claimed |
| EP-0637965-B1 | ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES | ISIS PHARMACEUTICALS INC (US) | 2002-10-16 | — | — | EP | claimed |
| WO-2001040515-A1 | GAPPED OLIGOMERS HAVING SITE SPECIFIC CHIRAL PHOSPHOROTHIOATE INTERNUCLEOSIDE LINKAGES | ISIS PHARMACEUTICALS, INC. (US) | 2001-06-07 | — | — | WO | claimed |
| US-20220025370-A1 | OLIGOMER-CONJUGATE COMPLEXES AND THEIR USE | IONIS PHARMACEUTICALS, INC. (US) | 2022-01-27 | — | — | US | disclosed |
| EP-3640332-A1 | OLIGOMER-CONJUGATE COMPLEXES AND THEIR USE | Ionis Pharmaceuticals, Inc. (US) | 2020-04-22 | — | — | EP | disclosed |
| US-20190136234-A1 | OLIGOMER-CONJUGATE COMPLEXES AND THEIR USE | IONIS PHARMACEUTICALS, INC. (US) | 2019-05-09 | — | — | US | disclosed |
| EP-3453761-A1 | OLIGOMER-CONJUGATE COMPLEXES AND THEIR USE | Ionis Pharmaceuticals, Inc. (US) | 2019-03-13 | — | — | EP | disclosed |
| EP-2751270-B1 | OLIGOMER-CONJUGATE COMPLEXES AND THEIR USE | IONIS PHARMACEUTICALS INC (US) | 2018-08-22 | — | — | EP | disclosed |
| US-10023861-B2 | Oligomer-conjugate complexes and their use | IONIS PHARMACEUTICALS, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| EP-2708541-B1 | 5,6-dihydroxy-isoindole derivatives as linkers for oligomer solid phase synthesis | ISIS PHARMACEUTICALS INC (US) | 2015-01-28 | — | — | EP | disclosed |
| EP-2751270-A1 | OLIGOMER-CONJUGATE COMPLEXES AND THEIR USE | Isis Pharmaceuticals, Inc. (US) | 2014-07-09 | — | — | EP | disclosed |
| EP-0643720-A1 | BINDING COMPETENT OLIGOMERS CONTAINING 2', 5' LINKAGES | GILEAD SCIENCES, INC. (US) | 1995-03-22 | — | — | EP | disclosed |
| EP-0637965-A1 | ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES | GILEAD SCIENCES, INC. (US) | 1995-02-15 | — | — | EP | disclosed |
| EP-0616612-A4 | NUCLEASE STABLE AND BINDING COMPETENT OLIGOMERS AND METHODS FOR THEIR USE. | GILEAD SCIENCES INC (US) | 1995-01-11 | — | — | EP | disclosed |
| WO-1994024144-A2 | ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PURINES | GILEAD SCIENCES, INC. (US) | 1994-10-27 | — | — | WO | disclosed |
| EP-0616612-A1 | NUCLEASE STABLE AND BINDING COMPETENT OLIGOMERS AND METHODS FOR THEIR USE | GILEAD SCIENCES, INC. (US) | 1994-09-28 | — | — | EP | disclosed |
| WO-1993024508-A1 | BINDING COMPETENT OLIGOMERS CONTAINING 2', 5' LINKAGES | GILEAD SCIENCES, INC. (US) | 1993-12-09 | — | — | WO | disclosed |
| WO-1993012135-A1 | NUCLEASE STABLE AND BINDING COMPETENT OLIGOMERS AND METHODS FOR THEIR USE | GILEAD SCIENCES, INC. (US) | 1993-06-24 | — | — | WO | disclosed |
| WO-1993010820-A1 | ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES | GILEAD SCIENCES, INC. (US) | 1993-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220025370-A1 | OLIGOMER-CONJUGATE COMPLEXES AND THEIR USE | DCLRE1B, NT5C3B, PAICS | PHGDH 3845/4885CA12 626/4885CA7 1290/4885 |
| US-10023861-B2 | Oligomer-conjugate complexes and their use | DCLRE1B, NT5C3B, PAICS | PHGDH 3845/4885CA12 626/4885CA7 1290/4885 |
| US-20190136234-A1 | OLIGOMER-CONJUGATE COMPLEXES AND THEIR USE | DCLRE1B, NT5C3B, PAICS | PHGDH 3845/4885CA12 626/4885CA7 1290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.